News | August 13, 2021
JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Deal signed with AOP Orphan for US commercial rights
The drug is indicated for mild and transient episodes of heart block
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The company posted net profit of Rs.321 crores for the period ended June 30, 2020.
The US business faced price erosion due to increased competition.
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Subscribe To Our Newsletter & Stay Updated
